Specifically, in vitro studies demonstrated that antibodies targeting Clec4e and Dectin-1 significantly reduced neutrophil-mediated cytotoxicity against both AT3 and LLC tumor cells, while antibodies against NKG2D showed no effect. This evidence concerns the gene CLEC7A and neoplasm.